Arrowhead Pharmaceuticals (ARWR) is trading higher as investors react to a fresh clinical update: the company said it presented new long-term (two-year) efficacy and safety data from an open-label extension study of plozasiran across a spectrum of hypertriglyceridemia (HTG). The read-through is strengthening confidence that Arrowhead’s triglyceride-lowering franchise can extend beyond its initial commercial beachhead in familial chylomicronemia syndrome (FCS) and into broader, higher-prevalence cardiometabolic indications. (natlawreview.com)

Plozasiran is already commercial as REDEMPLO for FCS following U.S. approval on November 18, 2025, but the bigger upside has been tied to expansion into severe hypertriglyceridemia (SHTG) and related populations where patient counts and payer attention are significantly larger. Long-term open-label extension results can help address investor concerns around durability and tolerability for a chronic cardiometabolic therapy, particularly as Arrowhead positions plozasiran for broader regulatory filings. (sec.gov)

Arrowhead has guided to multiple meaningful 2026 catalysts, including Phase 3 topline results from SHASTA-3/SHASTA-4 evaluating plozasiran in SHTG in the third quarter of 2026, and management has discussed plans for a supplemental filing after these pivotal readouts. With the stock sensitive to incremental signals ahead of pivotal data, traders often bid shares up on durable, longer-duration datasets that reduce perceived execution and safety risk going into registrational events. (finance.yahoo.com)

Key swing factors from here are: (1) the detailed content of the two-year dataset as investors digest durability, safety, and dosing implications; (2) any additional updates on early REDEMPLO launch progress; and (3) confirmation of timelines for the pivotal SHTG readouts and subsequent regulatory strategy. Any change in the expected Phase 3 timing, label-expansion pathway, or commercial traction could quickly reshape near-term sentiment around ARWR. (sec.gov)